Incyte Corporation (ETR:ICY)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.23B +57.9% |
| Revenue (ttm) | 5.09B +26.9% |
| Net Income | 1.41B +85.1% |
| EPS | 6.87 +79.7% |
| Shares Out | n/a |
| PE Ratio | 15.75 |
| Forward PE | 52.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 108.10 |
| Previous Close | 109.45 |
| Day's Range | 108.10 - 108.10 |
| 52-Week Range | 84.00 - 116.25 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental applicat...
Incyte initiated with a Buy at Canaccord
Canaccord initiated coverage of Incyte (INCY) with a Buy rating and $152 price target
Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital
Incyte (INCY) is expected to report updated data for KRAS G12D inhibitor ‘734, in combination with mFOLFIRINOX and GemNabP, at ESMO in October, with previous data showing “too little” to…
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) proudly recognizes and supports Incyte's Moments of Clarity campaign, a powerful storytelling initiative that highlights the l...
Incyte price target raised to $130 from $110 at Piper Sandler
Piper Sandler analyst Allison Bratzel raised the firm’s price target on Incyte (INCY) to $130 from $110 and keeps an Overweight rating on the shares following quarterly results. The firm…
Incyte price target raised to $104 from $99 at Bernstein
Bernstein raised the firm’s price target on Incyte (INCY) to $104 from $99 and keeps a Market Perform rating on the shares. The firm notes Incyte reported encouraging Q2 earnings.
Incyte Sales Growth Drives Share Price Gains
Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte price target raised to $137 from $121 at Mizuho
Mizuho raised the firm’s price target on Incyte (INCY) to $137 from $121 and keeps an Outperform rating on the shares.
Incyte price target raised to $155 from $131 at Leerink
Leerink analyst Andrew Berens raised the firm’s price target on Incyte (INCY) to $155 from $131 and keeps an Outperform rating on the shares.
Incyte price target raised to $120 from $110 at JPMorgan
JPMorgan raised the firm’s price target on Incyte (INCY) to $120 from $110 and keeps a Neutral rating on the shares.
Damora Therapeutics price target raised to $40 from $35 at Wedbush
Wedbush raised the firm’s price target on Damora Therapeutics (DMRA) to $40 from $35 and keeps an Outperform rating on the shares. Relevant to Damora Therapeutics, Incyte (INCY) updated its…
Incyte price target raised to $109 from $99 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Incyte (INCY) to $109 from $99 and keeps a Sector Perform rating on the shares after its Q2 earnings…
Incyte price target raised to $130 from $112 at BMO Capital
BMO Capital raised the firm’s price target on Incyte (INCY) to $130 from $112 and keeps a Market Perform rating on the shares. The company’s Commercial strength and increasingly de-risked…
Incyte price target raised to $150 from $136 at Guggenheim
Guggenheim raised the firm’s price target on Incyte (INCY) to $150 from $136 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q2 results.
Incyte price target raised to $119 from $104 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Incyte (INCY) to $119 from $104 and keeps an Equal Weight rating on the shares. A “solid” Q2 underscored consistency in the…
Incyte says EC approves Opzelura cream for treatment of AD
Incyte (INCY) announced that the European Commission has approved Opzelura cream for the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineu...
Incyte price target raised to $140 from $136 at BofA
BofA raised the firm’s price target on Incyte (INCY) to $140 from $136 and keeps a Buy rating on the shares following a “strong” Q2 performance and FY26 guidance raise.
Incyte price target raised to $150 from $140 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Incyte (INCY) to $150 from $140 and keeps a Buy rating on the shares. The company reported a “solid beat and raise”…
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis.
Incyte price target raised to $139 from $134 at Barclays
Barclays raised the firm’s price target on Incyte (INCY) to $139 from $134 and keeps an Overweight rating on the shares post the Q2 report. The company’s commercial trends remain…
Incyte price target raised to $145 from $123 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Incyte (INCY) to $145 from $123 and keeps a Buy rating on the shares. The company reported Q2 results, highlighted…
Incyte price target raised to $120 from $107 at Oppenheimer
Oppenheimer raised the firm’s price target on Incyte (INCY) to $120 from $107 and keeps an Outperform rating on the shares. The company reported solid Q2 results, driven by broad…
Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline
Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontinued further development of INCB160058…